Antony Mattessich Joins Amphista Therapeutics as CEO
Amphista Therapeutics Appoints New Chief Executive Officer
Amphista Therapeutics has taken a significant step forward by appointing Antony Mattessich as its new Chief Executive Officer (CEO). This appointment is expected to expedite the company’s growth trajectory, particularly in the development of its innovative Targeted Glue™ protein degraders that are set to transition into clinical trials.
Key Milestones and Growth Ahead
The hiring of Mattessich comes on the heels of remarkable progress made by Amphista in 2024. The company recently celebrated three major achievements that highlighted its pioneering capabilities: demonstrating in vivo efficacy, the ability to effectively target and degrade proteins within the central nervous system (CNS), and unveiling a novel mechanism of action for protein degradation.
Antony Mattessich's Background
Antony Mattessich brings a wealth of experience to Amphista, having a proven track record in steering programs from the initial discovery phase through clinical development and onto successful commercialization. Throughout his career, he has raised over $750 million to fund various biotechnology enterprises. Before joining Amphista, he served as the President and CEO of Ocular Therapeutix, a Nasdaq-listed company, where he successfully guided the development of treatments for conditions like Wet Age-Related Macular Degeneration.
Vision for Amphista
Upon his appointment, Mattessich expressed enthusiasm regarding his role at Amphista. He remarked, "2024 marks a pivotal year for Amphista, and I am thrilled to be part of a company with such distinctive technology in the targeted protein degradation sector at this exciting juncture in its development. My focus will include evolving Amphista's portfolio to turn innovative research into groundbreaking treatments that improve patients' lives."
Chairman’s Endorsement
Joshua Brumm, Chairman of Amphista's Board of Directors, echoed Mattessich's sentiments, stating, "Antony’s extensive background in drug development, alongside his capital markets insight, aligns perfectly with our plans to push our lead assets into clinical trials after this year's compelling new data on in vivo efficacy and CNS activity. We are excited to welcome Antony during such a transformational period for Amphista."
Recent Scientific Advancements
Earlier in 2024, Amphista revealed the success of its next generation bifunctional protein degraders. Furthermore, the company showcased a new mechanism of action for the degradation of BRD9, a promising target in the field of oncology. This innovative approach distinguishes itself from more traditional cereblon- or VHL-based technologies, reflecting Amphista’s commitment to advancing its groundbreaking TPD medicines.
About Amphista Therapeutics
Amphista Therapeutics is dedicated to revolutionizing treatment options for patients battling severe conditions, including cancer and neurodegenerative disorders, through the progression of next-generation targeted protein degradation therapies. Utilizing proprietary warhead chemistry and mechanistic expertise, Amphista continues to develop bifunctional Targeted Glue® agents with exceptional properties. This innovative approach not only aims for first-or-best-in-class drugs but also seeks to broaden the application of TPD therapies beyond traditional methodologies. The company was founded as a spin-out from the University of Dundee, driven by Professor Alessio Ciulli's expertise, and is backed by prominent investors and strategic partners.
For More Information
For any inquiries, please reach out to:
Amphista Therapeutics
John Goodall
Email: info@amphista.com
ICR Consilium
Amber Fennell, Namrata Taak, Emily Johnson
Email: amphista@consilium-comms.com
Tel: +44 (0)20 3709 5813
Frequently Asked Questions
What is Amphista Therapeutics?
Amphista Therapeutics is a biopharmaceutical company focused on developing next-generation targeted protein degradation therapies for challenging diseases.
Who is Antony Mattessich?
Antony Mattessich is the newly appointed CEO of Amphista Therapeutics, with extensive experience in drug development and company leadership.
What significant achievements has Amphista made in 2024?
Amphista has successfully demonstrated in vivo efficacy, targeted protein degradation in the CNS, and unveiled new mechanisms for its therapies.
What technologies does Amphista employ?
Amphista applies proprietary warhead chemistry to develop bifunctional Targeted Glue® agents that aim to enhance the effectiveness of TPD treatments.
How can I learn more about Amphista's developments?
For further information, you can visit Amphista's official website or contact their communication team directly.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Plastic Caps and Closures Market Set to Reach USD 96.28 Billion
- EzFill Holdings, Inc. Achieves NASDAQ Listing Compliance Again
- Polarean Imaging Welcomes Alan Huang as VP of Sales
- Coloplast A/S Share Trading Insights for Board and Executives
- RecycLiCo Battery Materials Appoints Dr. Maryam Rasouli as Principal Engineer
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- Global Cash Handling Device Market Growth Insights
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- Plumas Bank Unveils 2024 Corporate Citizenship Insights
- John Ballantyne Joins Glucotrack Board to Advance Innovation
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- Equip Exposition Appoints Chris Meecha as New Show Director
- Treasure Global Inc Appoints New Directors to Enhance Growth
- Roper Technologies to Showcase Innovations at GS Conference
- Henry Steinberg Takes Over as Global Head of EQT Exeter
- Kronos Bio to Showcase Research at Key Medical Conferences
- National Police Association Opposes New Liability Insurance Bill
- Trio Petroleum Corp Boosts Oil and Gas Reserves Estimates
- Veterinary Point of Care Diagnostics Market Forecast Growth
- Outlook Therapeutics to Present at Major Investment Conference
- MDWerks Partners with Green Glass Global to Boost Sales
- Femasys Highlights Innovation at H.C. Wainwright Conference
- Avenue Therapeutics Announces Participation in Investor Conferences
Recent Articles
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- John Ballantyne Joins Glucotrack Board to Advance Innovation
- Exploring Broadcom's Stock Movements and Price Levels Ahead
- DriveItAway Partners with AllShifts to Support Nurses' Mobility
- Callinex Begins 2024 Exploration at Pine Bay Project Initiative
- PhaseV to Showcase Innovative Clinical Trial Solutions
- Navigating Risks for Bullish Investors this September
- CoinW Launches Innovative Futures Grid and CTA Tools for Traders
- Spectral Medical Updates on Progress of Tigris Trial
- Video Conferencing Solutions Market to Hit $49.7 Billion by 2032
- Ashland Inc. Concludes Nutraceuticals Business Sale Agreement
- Castellum, Inc. Appoints Drew Merriman New Chief Operating Officer
- Orthofix Medical Inc. Faces Class Action: Important Investor Update
- Class Action Alert: MongoDB Investors Urged to Act Before Deadline
- Global Micellar Water Market Forecast: USD 5.8 Billion by 2033
- Exploring Future Potential: CrowdStrike and Amazon Securities
- GN Store Nord Share Transactions by Executives Unveiled
- Director Transactions: Insights into PDMR and Their Shares
- Shell plc Announces Share Purchase for Cancellation
- Exploring Promising Space Stocks for Future Growth
- THERAKOS™ CELLEX™ System Secures New EU CE Certification
- Caliway Initiates CBL-514 Phase 2b Study for Dercum's Disease
- QL Biopharm Unveils New Data on ZT002 at EASD Annual Meeting
- Suominen Corporation's Nomination Board Composition Update
- China-Africa Cooperation: Paving the Way for Modernization